New Horizons in Nephrology: Glomerular Disease 2026: Therapeutic Advances and Targeted Approaches

Glomerular disease is associated with morbidity and mortality in patients of all ages and is a common cause of end stage kidney disease. These include those that are commonly present with nephrotic syndrome (minimal change disease, FSGS and membranous nephropathy), the nephritic syndrome (vasculitis, lupus nephritis and IgA nephropathy), among others. Treatment often utilizes immunosuppressive regimens such as high dose corticosteroids, alkylating agents, calcineurin inhibitors, biologics and antimetabolites, which can be associated with significant side effects and morbidity. Thus, glomerular diseases present a difficult and unique challenge to both patients and nephrologists and are associated with high treatment costs and historically, have had poor renal outcomes. There have been significant recent advances in the field in both the diagnosis and treatment of glomerular diseases as well as in targeted therapies. Therefore, it is important for physicians to stay current with these new approaches to managing glomerular diseases. These therapeutic approaches are targeting previously known pathways like B-cell, complement and endothelin pathway. A refresher on the role of these pathways clarifies the role of these newly approved therapies.

1. Evaluate surrogate endpoints in glomerular diseases and apply them to assess treatment efficacy and trial design in clinical practice
2. Identify and differentiate novel-non-immunological and targeted therapeutic approaches (including B-cell and complement pathway modulators) for managing glomerular diseases, and incorporate them into patient treatment strategies
3. Describe the pathophysiology of podocytopathies (including minimal change disease and FSGS) IgA nephropathy, ANCA vasculitis, complement-mediated diseases (C3G, IC-MPGN, aHUS), lupus nephritis, and membranous nephropathy
4. Integrate recent genetic insights to guide diagnosis and personalized management of glomerular diseases
5. Analyze clinical cases of glomerular disease presentations, incorporating renal pathology findings, genetic testing results, and emerging biomarkers to formulate accurate differential diagnoses and evidence-based treatment plans
6. Compare and contrast current and investigational therapies for glomerular diseases, and discuss how to select appropriate patients for novel agents or clinical trials based on the latest mechanistic and outcome data.

LIVE AND VIRTUAL PRESENTATIONS
New Horizons in Nephrology: Glomerular Disease 2026: Therapeutic Advances and Targeted Approaches will be held Friday, September 18, 2026, by in-person and live-stream virtual attendance. The in-person and virtual presentations will follow the scheduled agenda in real time (EDT).

IN-PERSON ATTENDANCE
REGISTRATION FEE
The fee to attend in-person is $150 for all attendees. All pre-registered, in-person attendees will receive access to the conference, continental breakfast, lunch, and breaks. Registration also includes access to view the recorded speaker presentations online for one year. Walk-ins are discouraged. Please register no later than September 16, 2026, so an accurate count may be made for food and beverages.

MEETING LOCATION
New Horizons in Nephrology: Glomerular Disease 2026: Therapeutic Advances and Targeted Approaches will be held at the University of Pennsylvania, in the Smilow Center for Translational Research, Rubenstein Auditorium, located in the Perelman Center for Advanced Medicine, 1st floor, 3400 Civic Center Boulevard, Philadelphia, PA 19104.

Parking
Parking is available at the 3600 Civic Center Boulevard Garage at $20 per day. A free shuttle service from the Parking garage to Perelman is also available.

VIRTUAL ATTENDANCE
REGISTRATION FEE
The fee to attend virtually is $100 and the deadline to register virtually is also September 16, 2026.

Attendees registered to attend virtually will receive an email 48 hours before the conference that includes the link to join the conference. All virtual attendees are required to sign in with their first name, last name, and email address, in order to be marked as attended and receive credit.

All registrants will receive conference materials via email 48 hours in advance of the meeting.

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Designation of Credit
Physicians: Penn Medicine designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 7.75 Category 1 credits for completing this activity.

CANCELLATION AND REFUND POLICY
In order to process refunds for course withdrawals, cancellations must be received via email by September 11, 2026, and are subject to a service charge equivalent to 10% of the registration fee. No refunds will be issued thereafter. Please email [email protected] or [email protected] regarding cancellations.

The University of Pennsylvania reserves the right to cancel or postpone this course due to unforeseen circumstances. In the event of a cancellation or postponement, the University will refund registration fees but is not responsible for fees assessed for travel or hotels.